Home
    • Plans Blog Contact
    Compass Pathways Plc logo

    Compass Pathways Plc

    CMPS
    Last price US$13.45
    Market cap US$1.8b
    12M price change 217.22%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Universal Health Services IncUHS Industry peer DaVita HealthCare Partners IncDVA Industry peer CHEMED CORPCHE Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Compass Pathways Plc Overview

    Industry: Medical Care Facilities

    Sector: Healthcare

    COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom. COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatmen Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Compass Pathways Plc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Aug 05, 2026

    Quarterly result summary

    Net loss was -$253.8M. R&D expense was $29.2M.

    Net loss -$253.8M reported
    R&D expense $29.2M reported
    G&A expense $23.2M reported
    Cash $433.3M reported

    What changed

    • Review the SEC source filing for the full reported results and management commentary.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 8-K Aug 05, 2026 SEC filing 10-Q Aug 05, 2026 SEC filing 10-Q May 13, 2026 SEC filing 8-K May 13, 2026 Earnings release Earnings release May 13, 2026 SEC filing 10-K Mar 24, 2026 SEC filing 8-K Mar 24, 2026 Earnings release Earnings release Mar 24, 2026 SEC filing 10-Q Nov 04, 2025 SEC filing 8-K Nov 04, 2025 Earnings release Earnings release Nov 04, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 2.00/5
    Compass Pathways Plc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Medical Care Facilities industry , Universal Health Services Inc , DaVita HealthCare Partners Inc , CHEMED CORP are companies with high ratings.

    Return on Equity

    Score 0.27/5
    Compass Pathways Plc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Compass Path... CMPS US$1.8b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.21/5
    Compass Pathways Plc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Compass Path... CMPS US$1.8b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Medical Care Facilities industry , Universal Health Services Inc , DaVita HealthCare Partners Inc , CHEMED CORP are companies with high ratings.

    Leverage

    Score 3.63/5
    Compass Pathways Plc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Compass Path... CMPS US$1.8b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Reported currency
    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Compass Pathways Plc logo

    Compass Pathways Plc

    US$13.45

    US$1.8b

    -0.74%

    217.22%